Key Points Novo Nordisk stock lost 40% of its value in 2025. The stock is already trading up 22% in 2026. 10 stocks we like better than Novo Nordisk › 2025 was a miserable year to own Novo Nordisk (NYSE: NVO) stock. Shares of the Danish pharmaceuticals giant and inventor of Wegovy and Ozempic crashed 40% last year as the company steadily lost market share to rivals such as Eli Lilly (NYSE: LLY), which has competing Mounjaro and Zepbound drugs, and Novo Nordisk's earnings fell in tandem. Novo Nordi ...